Payment overview · 2025
General Payments
$148.19
9 reported records · 5 companies
Healthcare provider profile · identity verified
Chet M Gentry, MD
Allopathic & Osteopathic Physicians|Family Medicine · COOKEVILLE, TN · NPI 1851380406
Verified facts
What the public records show
CMS Open Payments records show Chet M Gentry, MD received $148.19 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.97 | 54.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.00 | 12.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.28 | 12.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.14 | 10.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.80 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $148.19 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.19 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.19 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.78 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 566 | 172 |
| Levothyroxine Sodium | Levothyroxine Sodium | 510 | 148 |
| Lisinopril | Lisinopril | 427 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 119 |
| Losartan Potassium | Losartan Potassium | 338 | 105 |
| Tamsulosin Hcl | Tamsulosin Hcl | 297 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 95 |
| Gabapentin | Gabapentin | 281 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 87 |
| Omeprazole | Omeprazole | 256 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 250 | 77 |
| Trazodone Hcl | Trazodone Hcl | 243 | 78 |
| Furosemide | Furosemide | 241 | 81 |
| Famotidine | Famotidine | 219 | 63 |
| Eliquis | Apixaban | 210 | 51 |
| Metformin Hcl | Metformin Hcl | 209 | 69 |
| Montelukast Sodium | Montelukast Sodium | 202 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 61 |
| Sertraline Hcl | Sertraline Hcl | 171 | 42 |
| Ozempic | Semaglutide | 164 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 160 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 51 |
| Simvastatin | Simvastatin | 143 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 136 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 40 |
| Potassium Chloride | Potassium Chloride | 119 | 35 |
| Meloxicam | Meloxicam | 113 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 110 | 24 |
| Donepezil Hcl | Donepezil Hcl | 103 | 22 |
| Allopurinol | Allopurinol | 102 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 30 |
| Metformin Hcl Er | Metformin Hcl | 87 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 23 |
| Methylprednisolone | Methylprednisolone | 73 | 56 |
| Buspirone Hcl | Buspirone Hcl | 71 | 22 |
| Cefdinir | Cefdinir | 69 | 60 |
| Warfarin Sodium | Warfarin Sodium | 68 | 12 |
| Jardiance | Empagliflozin | 67 | 20 |
| Chlorthalidone | Chlorthalidone | 65 | 19 |
| Mounjaro | Tirzepatide | 64 | 14 |
| Carvedilol | Carvedilol | 61 | 20 |
| Atenolol | Atenolol | 59 | 19 |
| Levetiracetam | Levetiracetam | 57 | 15 |
| Memantine Hcl | Memantine Hcl | 57 | 18 |
| Lorazepam | Lorazepam | 54 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Pregabalin | Pregabalin | 52 | 13 |
| Tramadol Hcl | Tramadol Hcl | 51 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 12 |
| Trulicity | Dulaglutide | 48 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 22 |
| Prednisone | Prednisone | 45 | 13 |
| Ondansetron Odt | Ondansetron | 44 | 20 |
| Finasteride | Finasteride | 42 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 12 |
| Azithromycin | Azithromycin | 39 | 33 |
| Lovastatin | Lovastatin | 39 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 13 |
| Xarelto | Rivaroxaban | 39 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 13 |
| Ezetimibe | Ezetimibe | 34 | 16 |
| Nystatin | Nystatin | 34 | 17 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | 13 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | 12 |
| Spironolactone | Spironolactone | 28 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 12 |
| Ibuprofen | Ibuprofen | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 14 |
| Fluconazole | Fluconazole | 25 | 17 |
| Ketoconazole | Ketoconazole | 25 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | 11 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Nucynta Er | Tapentadol Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | 13 |
| Lacosamide | Lacosamide | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 11 |
| Cephalexin | Cephalexin | 19 | 19 |
| Estradiol | Estradiol | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Xtampza Er | Oxycodone Myristate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Flunisolide | Flunisolide | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $148.19 · 9 records | Novo Nordisk Inc | BREZTRI, Cologuard Collection Kit, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error